PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.:

09/856,969

Confirmation No.: 5142

Applicant(s):

Cayuela et al. August 1, 2001

Filed: Art Unit:

1645

Examiner:

Jana A. Hines

Title:

SELECTION AND USES OF LACTIC ACID BACTERIA STRAINS

MODULATING NON-SPECIFIC IMMUNITY

Docket No.:

033339/234602

Customer No.: 00826

Mail Stop Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

#### RESPONSE

Sir:

In response to the Office Action dated August 26, 2003, Applicants request reconsideration by the Examiner in light of the following comments.

In the August 26, 2003 Official Action, the Examiner has taken the position that Applicants' amendment dated May 20, 2003 is not fully responsive to the previous Official Action. For the reasons set forth below, Applicants' prior response was indeed fully responsive to the Official Action. The claims as amended are directed to the same invention as the previously elected claims of Group I.

Claims 1-6 and 10-12 as now presented are directed to a method for regulating the inflammatory response of enterocytes. Thus, these claims are directed to a use of the composition which was the subject matter of Claims 1-6 and 10-12 as presented in the Preliminary Amendment submitted at the time of filing..

According to PCT Rule 13 and 37 C.F.R. 1.475(b)(2), the following combination of categories of claims will be considered to have unity of invention: "A product and a process of use of said product". Therefore, according to these standards, there is unity of invention between the elected claims of group I (i.e. earlier-presented Claims 1-6 and 10-20) which are directed to a

Appl. No.: 09/856,969 Filed: August 1, 2001

Page 2

product in the nature of a composition and Claims 1-6 and 10-12 as now presented, which are directed to a use of said composition. The claims as now presented are fully consistent with the elected invention of Group I.

Further, the regulatory effect of the composition on the inflammatory response of enterocytes results from the ability of the lactic acid bacteria of this composition to decrease the production of NO by cultures of enterocytes preactivated with pro-inflammatory cytokines and bacterial LPS, which was the essential technical feature of the composition of previous Claims 1-6.

The pending method claims correspond to the original Claims 1-6 of PCT 00/28943, which were "second therapeutic use" claims (the European equivalent of United States "method of treatment" claims). Thus, the pending method claims are actually directed to an originally-claimed invention, and the PCT search, as well as the International Preliminary Examination were performed on the basis of this invention.

For the reasons noted, it should be evident that the claims as now presented are closely related to the previous claims and are indeed directed to the previously elected invention.

Therefore, Applicants respectfully request the Examiner to proceed with an examination on the merits of the elected claims as now presented.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those that may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,

HECI CENTRAL F

SEP 2 4 2003

Raymond O. Linker, Jr. Registration No. 26,419

**OFFICIAL** 

Appl. No.: 09/856,969 Filed: August 1, 2001

Page 3

Customer No. 00826
ALSTON & BIRD LLP
Bank of America, Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Charlotte Office (704) 444-1000
Fax Charlotte Office (704) 444-1111
CLT01/4611635v1

#### CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the US Patent and Trademark Office at Fax No. (703) 872-9306 on the date shown below.

Janet F. Sherrill

Date

Date:

ALSTON BIRD LLP (60)

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

# ALSTON&BIRD LLP

101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 704-444-1000 Fax: 704-444-1111

CENTRAL FAX CENTER

SEP 2 4 2003

### **TELECOPY** PLEASE DELIVER AS SOON AS POSSIBLE

	C		İ		Δ	
V	Γ	5			H	

September 23,	2003			
Recipient:		Company:		
Examiner Jana A. Hines		U.S. PATENT & TRADEMARK OFFICE		
Fax Number:		Voice Number:		
(703) 872-930	6			
Sender:				
Raymond O. I.	inker, Jr.			
Message:				
Application No.	(	L NON-FINAL RESPONSE		
:	•	Number of Pages: (including cover page) 4		
IF NOT RE	CEIVED PROPI	ERLY, PLEASE NOTIFY US IMMEDIATELY AT.		
USER CODE:	LINKR	REQUESTED BY: Jan Sherrill - 1163		
CLIENT/MATTER:	033339/234602	OPERATOR:		

Alston & Bird